Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Trial With Dose Expansion of the Bruton‟s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab and Lenalidomide in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Next Previous
Trial Profile

Phase Ib Trial With Dose Expansion of the Bruton‟s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab and Lenalidomide in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs Ibrutinib (Primary) ; Lenalidomide; Rituximab
  • Indications Diffuse large B cell lymphoma; Nervous system neoplasms
  • Focus Adverse reactions

    • Most Recent Events

    • 22 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 15 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Jan 2019.
    • 04 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top